GSK's Tafinlar granted 'breakthrough' status in NSCLC
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Tafinlar (dabrafenib) is the latest drug to join the crowd of products deemed breakthrough therapies by the FDA, which granted the coveted title to the medicine as a treatment for patients with metastatic BRAF V600E mutation-positive non-small-cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.